Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.

Abstract

In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).

• Authors: Javier Cortes, Chris Twelves
• Journal: The breast journal (Breast J) Vol. 26 Issue 7 Pg. 1347-1351 (07 2020) ISSN: 1524-4741 [Electronic] United States
• PMID: 31782589 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 The Authors. The Breast Journal published by Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents
• Furans
• Ketones
• eribulin

Topics

• Antineoplastic Agents (therapeutic use)
• Breast Neoplasms (drug therapy)
• Disease-Free Survival
• Female
• Furans (therapeutic use)
• Humans
• Ketones